Article

Cannabis use in first-treatment bipolar I disorder: relations to clinical characteristics

Early Intervention in Psychiatry (Impact Factor: 1.74). 05/2014; DOI: 10.1111/eip.12138

ABSTRACT AimsThe aim of this study was to investigate the associations between recent cannabis use, current symptomatology and age at onset of first manic, depressive and psychotic episodes in a large sample with first-treatment bipolar I disorder (BD I).Methods
One hundred one patients with first-treatment Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) bipolar I disorder were included as part of the Thematically Organized Psychosis study. The Structural Clinical Interview for DSM-IV was used for DSM-IV diagnosis and identification of episodes of illness. Earlier suicide attempts were recorded. Manic, depressive and psychotic symptoms were rated using the Young Mania Rating Scale, Inventory of Depressive Symptoms and Positive and Negative Syndrome Scale correspondingly. Cannabis use within the six last months was recorded.ResultsAfter controlling for confounders, recent cannabis use was significantly associated with lower age at onset of first manic and psychotic episode, but not with onset of first depressive episode (both P < 0.05). Recent use was also associated with more lifetime suicide attempts (P < 0.01). No group differences were found on symptom levels.Conclusions
The present study confirms earlier findings of an association between cannabis use and a lower age at onset. Recent cannabis use was also associated with more lifetime suicide attempts. The current findings suggest that recent cannabis use is associated with a more severe course of illness in the early phase of BD I.

3 Followers
 · 
73 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ZUSAMMENFASSUNG Hintergrund: Cannabis ist die am häufigsten konsumierte illegale Droge welt-weit. In Deutschland wird sie jährlich von circa 4,5 % aller Erwachsenen ver-wendet. Ein intensiver Cannabiskonsum ist mit gesundheitlichen Risiken assozi-iert. Zur Behandlung von gesundheitlichen Störungen infolge von Cannabisge-brauch stehen evidenzbasierte Interventionsmöglichkeiten zur Verfügung. Methode: Es erfolgte eine selektive Literaturrecherche in PubMed mit besonde-rem Schwerpunkt auf systematischen Reviews, Metaanalysen, Kohortenstudien, randomisiert-kontrollierten Studien (RCTs), Fallkontrollstudien und Behandlungs-leitlinien. Ergebnisse: Der Gehalt von Delta-9-Tetrahydrocannabinol in Cannabisprodukten steigt durch Züchtung weltweit an, wohingegen Cannabidiol häufig nicht mehr nachweisbar ist. Abhängig von Alter, Dosis, Frequenz, Applikationsform, Situation und individueller Disposition eines Menschen können unterschiedliche akute Folgeschäden durch Cannabiskonsum auftreten. Hierzu gehören Panikattacken, psychotische Symptome, beeinträchtigte Aufmerksamkeit, mangelnde Konzen-tration, gestörte motorische Koordination und Übelkeit. Insbesondere ein hoch-dosierter, langjähriger und intensiver Cannabisgebrauch sowie ein Konsumbe-ginn im Jugendalter kann mit einer Abhängigkeit (DSM-5; ICD-10), spezifischen Entzugssymptomen, kognitiven Einbußen, affektiven Störungen, Psychosen, Angststörungen und körperlichen Schädigungen (vor allem respiratorische und kardiovaskuläre Erkrankungen) einhergehen. Eine Kombination aus Motivations-förderung, kognitiver Verhaltenstherapie und Kontingenzmanagement sind aktu-ell die effektivsten Behandlungsansätze der Cannabisabhängigkeit (Evidenzgrad: 1a). Für Jugendliche werden ebenfalls familientherapeutische Interventionen empfohlen (Evidenzgrad: 1a). Aufgrund geringer Evidenz können bisher keine pharmakologischen Behandlungsempfehlungen gegeben werden. Schlussfolgerungen: Weitere Forschung ist notwendig, um die Kausalität des Zu-sammenhangs von intensivem Cannabiskonsum und möglichen Folgen für die körperliche und psychische Gesundheit zu klären. Gesundheitliche Störungen in-folge von Cannabiskonsum können effektiv behandelt werden. ►Zitierweise Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW: Risks associated with the non-medicinal use of cannabis.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cannabis is the most commonly consumed illicit drug around the world; in Germany, about 4.5% of all adults use it each year. Intense cannabis use is associated with health risks. Evidence-based treatments are available for health problems caused by cannabis use. Selective literature review based on a search of the PubMed database, with special emphasis on systematic reviews, meta-analyses, cohort studies, randomized controlled trials (RCTs), case-control studies, and treatment guidelines. The delta-9-tetrahydrocannabinol content of cannabis products is rising around the world as a result of plant breeding, while cannabidiol, in contrast, is often no longer detectable. Various medical conditions can arise acutely after cannabis use, depending on the user's age, dose, frequency, mode and situation of use, and individual disposition; these include panic attacks, psychotic symptoms, deficient attention, impaired concentration, motor incoordination, and nausea. In particular, intense use of high doses of cannabis over many years, and the initiation of cannabis use in adolescence, can be associated with substance dependence (DSM-5; ICD-10), specific withdrawal symptoms, cognitive impairment, affective disorders, psychosis, anxiety disorders, and physical disease outside the brain (mainly respiratory and cardiovascular conditions). At present, the most effective way to treat cannabis dependence involves a combination of motivational encouragement, cognitive behavioral therapy, and contingency management (level 1a evidence). For adolescents, family therapy is also recommended (level 1a evidence). No pharmacological treatments can be recommended to date, as evidence for their efficacy is lacking. Further research is needed to elucidate the causal relationships between intense cannabis use and potential damage to physical and mental health. Health problems due to cannabis use can be effectively treated.
    Deutsches Ärzteblatt 05/2015; 112(16):271-8. DOI:10.3238/arztebl.2015.0271 · 3.61 Impact Factor
  • Source
    Deutsches Ärzteblatt International 05/2015; · 3.61 Impact Factor